Temozolomide

For research use only.

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

68 publications

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 64 In stock
USD 70 In stock
USD 170 In stock
USD 290 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Temozolomide has been cited by 68 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NUnCNGZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWC0PEBp Ml\rTWM2OD1zM{muNlDjiIoEsfMAjVUvQTVizszN MlmzNlU6PjB{OEK=
KellyCis83 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDIeWppPDhiaB?= NGrCNGFKSzVyPUK1NU4xOOLCidMx5qCKOTVwN{Wg{txO NYLtPGNZOjV7NkCyPFI>
SK-N-AS NF7JfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK0Wlg2PDhiaB?= MWLJR|UxRTJ{Nz63NQKBkcLz4pEJNlIvOTVizszN MlXRNlU6PjB{OEK=
SK-N-ASCis24 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEi2bXc1QCCq NYDmSY5xUUN3ME20PFAvPjEkgJpCtgKBkTFyMT6xOUDPxE1? NGOzdYczPTl4MEK4Ni=>
CHP-212 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXG0PEBp NWX6UYJOUUN3ME23Mlk46oDLwsJihKkxNjZ7IN88US=> NUPuVHRPOjV7NkCyPFI>
CHP-212Cis100 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrpOoE1QCCq NUfPSVFRUUN3ME25MlU26oDLwsJihKkxNjh6IN88US=> MUOyOVk3ODJ6Mh?=
U87  MkXDSpVv[3Srb36gRZN{[Xl? MV6xNFAh|ryP MUGyOE04OiCq NIfrZ|lqdmS3Y3XzJGRkWjFiZYjwdoV{e2mxbh?= NH\xT5YzPThyOEi2PC=>
LN229 MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi0VHgxNTVyIN88US=> M2TmPGlEPTB;MU[g{txO M2jaSlI2PzVyMkez
TR-LN229 NXXiUXNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSwMVUxKM7:TR?= Ml\UTWM2OD15NzFOwG0> M{m5XlI2PzVyMkez
U87  NUTsd|NJSXCxcITvd4l{KEG|c3H5 NYfkfJJ1OOLCk{KwNQKBkcL3TR?= MlLBNlQhcA>? MV\lcohidmOnczDDVUBqdmS3Y3XkJIFxd3C2b4Ppdy=> NXWyXJFzOjV4OEG2Olg>
U251MG Ml3uRZBweHSxc3nzJGF{e2G7 MYOxNFDDqM7:TR?= NUH1WIg1PDhiaB?= NHLE[VlRSlN? NHj5R2hqdmS3Y3XzJIFxd3C2b4Ppdy=> NYTxNm0yOjV4OEC0OlQ>
U87MG MlnwRZBweHSxc3nzJGF{e2G7 M2fHNFExOMLizszN MWW0PEBp M3zCVnBDWw>? MkfqbY5lfWOnczDhdI9xfG:|aYO= MY[yOVY5ODR4NB?=
U87 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfiUYV[PTBvM{WwJO69VQ>? M3PFbVQ5yqCqwrC= NEjmOXFqdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? NVHlfXg3OjV3NUSyNlM>
U118  NU\iRphlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXtU|I2OC1|NUCg{txO NH\2XlY1QMLiaNMg M4fQUolvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 NGPCZXQzPTV3NEKyNy=>
U87 NFnGd|NHfW6ldHnvckBCe3OjeR?= NEn6XlUzPTBxM{WwJO69VQ>? NVzpS4NMPDkEoHlCpC=> MYXlcohidmOnczDUUXgucW6mdXPl[EBxNVCNQz3wZY4h\GWlcnXhd4U> MWmyOVU2PDJ{Mx?=
U118  M3zvPWZ2dmO2aX;uJGF{e2G7 MoDYNlUxNzN3MDFOwG0> NEfMeHc1QMLiaNMg NYfjXIRK\W6qYX7j[ZMhXE2[LXnu[JVk\WRicD3QT2MueGGwIHTlZ5Jm[XOn NUCwTWp1OjV3NUSyNlM>
U87 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyyOVAwOzVyIN88US=> NV25XWJ2PDkEoHlCpC=> M1fQVolv[3KnYYPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuczDpckBUKGGwZDDHNk9OyqClb4Ty[YF1\WRid3n0bEBVVVh? MViyOVU2PDJ{Mx?=
A375 M3TQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS0OFjDqGkEoB?= MVHJR|UxRTJ4NTFOwG0> MmjCNlU2OjR3NUK=
A2058 M1\Gcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDyWnM1QMLiaNMg NV;nTnhLUUN3ME2xNkDPxE1? M1HSeVI2PTJ2NUWy
M238 NYrtT3FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3OPZExPDkEoHlCpC=> MnvXTWM2OD12MDFOwG0> MVyyOVUzPDV3Mh?=
M249 MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfIXVg1QMLiaNMg M1r3fWlEPTB;MkW0JO69VQ>? MnnONlU2OjR3NUK=
M21 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlniOFjDqGkEoB?= MYHJR|UxRTJ{MTFOwG0> MkDENlU2OjR3NUK=
U251 MUTDfZRwfG:6aYT5JGF{e2G7 MX6yNEDPxE4EoB?= NYfGSo4xPDkEoHlCpC=> NEXifoZz\WS3Y3Xkd{B1cGVicHXyZ4VvfGGpZYOgc4Yh[2:ub37p[ZMh\m:{bXXk MWKyOVQ{PDN6MR?=
LN229 MW\DfZRwfG:6aYT5JGF{e2G7 NEnuO|czOCEQvF5CpC=> MUe0POKhcMLi NH\vXG9z\WS3Y3Xkd{B1cGVicHXyZ4VvfGGpZYOgc4Yh[2:ub37p[ZMh\m:{bXXk NUjOU3dkOjV2M{SzPFE>
U373MG-LUC NXvybWhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfSO|IhcA>? M3n2UGlEPTB-NkCwJO69VQ>? MkPlNlU1OzF7NUO=
U87  M4\ycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvwfpkzPS1{MECg{txO NI\tdZY1QMLiaNMg MY\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NY\LNFRMOjV2MEC3OFU>
U251 MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DsZlI2NTJyMDFOwG0> MYK0POKhcMLi NYnFTHUzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3PMWFI2PDByN{S1
U251 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSxNFAuPDByIN88US=> NWPM[GQzPzJxOU[gbC=> MnXBeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi NY[xVJhNOjV|N{WyO|E>
U373 M{XGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVixNFAuPDByIN88US=> M3n3UlczNzl4IHi= MXX0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NEjZWHgzPTN5NUK3NS=>
U343 NF7HUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\6ZXpWOTByLUSwNEDPxE1? M3[x[lczNzl4IHi= NF;Qe2N1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= M2fmVVI2Ozd3Mkex
U87MG-luc2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnnNVAxNTRyMDFOwG0> Mni5O|IwQTZiaB?= MoTReIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi NFi0bVgzPTN5NUK3NS=>
U87 MWXGeY5kfGmxbjDBd5NigQ>? NEHE[5MzODBizszN NWLGbJNkPDhiaB?= MXzpcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v M2i2eVI2OzN5N{Kx
U251 M4G3XWZ2dmO2aX;uJGF{e2G7 NV3rV|JWOjByIN88US=> MVm0PEBp M4rPUYlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? NXLDOI41OjV|M{e3NlE>
A172 M3;KdWZ2dmO2aX;uJGF{e2G7 MoPkNlAxKM7:TR?= NF\WfZU1QCCq Mn7QbY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? M4DWOFI2OzN5N{Kx
U251 NH;WU5VHfW6ldHnvckBCe3OjeR?= MUCyNFAh|ryP M4LXc|Q5KGh? MmnVbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? MnTRNlU{Ozd5MkG=
A172 NYfuRYNvTnWwY4Tpc44hSXO|YYm= MlzWNlAxKM7:TR?= NIC4Tnc1QCCq NXi2UXdvcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEKUQ1GxMEBDWkODMjygVmFFPTFiYX7kJGZCVkOGMh?= MXGyOVM{Pzd{MR?=
U87 NUDnXGVDTnWwY4Tpc44hSXO|YYm= NXzEbI9tOjByIN88US=> NGLGXFQzPC95Mj:xNlAhcA>? MmjmbY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6 NXjHSVYzOjV|M{e3NlE>
U251 MUjGeY5kfGmxbjDBd5NigQ>? MlrMNlAxKM7:TR?= MnmwNlQwPzJxMUKwJIg> M13HeYlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MYWyOVM{Pzd{MR?=
A172 NVP1fYtnTnWwY4Tpc44hSXO|YYm= MXWyNFAh|ryP NFLvOlkzPC95Mj:xNlAhcA>? MWrpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> MVGyOVM{Pzd{MR?=
SNB19V M{H5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XZflch\A>? MmD0SG1UVw>? NUDoc2NlT0l3ME2zOU44yrFzMjFOwG0> NH3tfnIzPTJ5N{S0NS=>
SNB19M NFjWb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XC[lch\A>? MljJSG1UVw>? M1W3PWdKPTB;NE[5MlnDuTh6IN88US=> NEj0[FYzPTJ5N{S0NS=>
SNB19VR MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\hd|ch\A>? MlPLSG1UVw>? MYfHTVUxRTJ6MD6yxtEyQCEQvF2= MljsNlUzPzd2NEG=
U373V MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nBRlch\A>? MWnEUXNQ M3W2[GdKPTB;NkiuNOKyOzJizszN MW[yOVI4PzR2MR?=
U373M NELXSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCweoo4KGR? NXXZV2d3TE2VTx?= NYPxTId3T0l3ME2zOlgvP8LzOE[g{txO M1HYPVI2Ojd5NESx
U373VR MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv4dYRbPyCm NGT3WI1FVVOR MomxS2k2OD1{OEiuPOKyOzNizszN NYfnOHhnOjV{N{e0OFE>
U87MG NF\3[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[3JIQ> MW\EUXNQ NIr5PXBIUTVyPUO4MlPDuTJyIN88US=> NWCyXpQ4OjV{N{e0OFE>
HCT116 M3zzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe4XWdPPyCm NFvjV5ZFVVOR NVP6TGFIT0l3ME21O|kvQcLzM{Kg{txO Mnn1NlUzPzd2NEG=
DLD1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVS3JIQ> NXG5fJFHTE2VTx?= MlXuS2k2OD13MEGuOOKyQTNizszN MYSyOVI4PzR2MR?=
MRC5 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjBPFBIPyCm NIf1SIdFVVOR NH;Cc4xIUTVyPUS0PU41yrF6IN88US=> MWqyOVI4PzR2MR?=
SNB19V  NUfBSGQ5TnWwY4Tpc44hSXO|YYm= MYCxNFAh|ryPwrDUUXo> MWGwMVczKGh? M2fvUolv[3KnYYPld{DPu0h{QWig[ZhxemW|c3nvckBj\XS5ZXXuJFE3KGGwZDC3NkBp NEDFZZozPTJ5N{S0NS=>
T98G  NVfXbZBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm1M|ExNzF3IN88US=> NXHDSFdHOjUEoHi= M4TBWIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnLXTldIVv\GWwdHz5JIFnfGW{IHPvcoNwdWm2YX70MZRmdW:8b3zvcYll\SC5aYToJG5R\TZvUFTU NULjeZJSOjV{NkK5OlE>
U251  MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7LOU8yOC9zNTFOwG0> NUHrfpVxOjUEoHi= M3\4T4lv\HWlZYOgZ4VtdCCmZXH0bEBld3OnLXTldIVv\GWwdHz5JIFnfGW{IHPvcoNwdWm2YX70MZRmdW:8b3zvcYll\SC5aYToJG5R\TZvUFTU NYqw[3NpOjV{NkK5OlE>
T98G  NYfGelNITnWwY4Tpc44hSXO|YYm= M1i4eFE2KM7:TR?= NV63c5dLOjUEoHi= Moe5bY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| M{LEW|I2OjZ{OU[x
U251  MV;GeY5kfGmxbjDBd5NigQ>? MVKxOUDPxE1? MVOyOOKhcA>? NFnhUIVqdmO{ZXHz[ZMhTE6DLX\yZYdu\W62YYTpc44hcW5iTmDlOk1RTFRidILlZZRm\CCpbHnvcYEh[2WubIO= MoTQNlUzPjJ7NkG=
U-87 MG NXPVSoo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXW3NkBp MkO1TWM2OD1yLkmzJI1OyqB? NXXv[HdiOjV{NEWzN|I>
U-118 MG M4DvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf0SJY4OiCq MnXTTWM2OD1zLkC1JI1OyqB? NVjvN|Q6OjV{NEWzN|I>
U87 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;NbWEzPCCq MYLJR|UxRTJ4MD6zOEDPxE4EoB?= M13TVlI2OTd|MkOz
U87 GSLCs Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKyOEBp NF3lcIRKSzVyPUe2Ok4yOSEQvF5CpC=> MXuyOVE4OzJ|Mx?=
U87MG NHjVTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rNcFczKGh? MUTJR|UxRTF3Lk[yOUDPxE4EoB?= MmX5NlUxPTB7MUW=
U251 M2nLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYixNFAuPDByIN88US=> NWj2eFk{PDhiaB?= NUnvOGtXTE2VTx?= MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mmj5NlQ3OjN5M{[=
U87 M4jwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKxNFAuPDByIN88US=> Mlr1OFghcA>? MUHEUXNQ M2PjbIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUOyOFYzOzd|Nh?=
MDA-MB-231-br MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHkNE0yOCEQvF2= NWTKdmt[PDhiaB?= NVjjfoluTE2VTx?= Mnz2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYqyOFYzOzd|Nh?=
HCC-1937 NI\ofmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSwNE0{ODBizszN NFW4R|I1QCCq M{jxNmROW09? MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF7Wc3UzPDZ{M{ezOi=>
MDA-MB-231 NFzrcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLoNE01OCEQvF2= M2nlZ|Q5KGh? MkPUSG1UVw>? MXLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MoPZNlQ3OjN5M{[=
MDA-MB-468 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPjNE02ODBizszN Ml;wOFghcA>? NYjZdWdwTE2VTx?= NIG0XlBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXOyOFYzOzd|Nh?=
T47D NWK2PFdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLvNE0yODBizszN MlnXOFghcA>? MkPBSG1UVw>? MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M2rEVVI1PjJ|N{O2
MCF7 NVXjb3h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmwMVExODBizszN NWjRS3hWPDhiaB?= Mn;xSG1UVw>? NELXTmRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWLoPFJ6OjR4MkO3N|Y>
Hs683 NYjpTmpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHpSVlnOC1zMECwJO69VQ>? NF\nWFE6PiCq NXm0R4RvUUN3ME2xNlgvQSEQvF2= NE\3eWkzPDR7NUmwOy=>
U87 NUTrRpFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7pNE0yODByIN88US=> NWrnfYEzQTZiaB?= MX;JR|UxRTF6LkS1JO69VQ>? Mn;jNlQ1QTV7MEe=
LNZ308 M133bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\LUFQxNTFyMECg{txO NUTOPZA4QTZiaB?= MnXoTWM2OD1|Mk[uO{DPxE1? M2nDZVI1PDl3OUC3
U87 NV21[ZhySXCxcITvd4l{KEG|c3H5 M2jSU|ExOCEQvF2= MofxOFghcA>? MkHLSG1UVw>? M2nad4lv[3KnYYPld{B1cGViY3HzdIF{\S1|L{egZYN1cX[rdIm= M2nG[lI1PDhzNUi2
U251  NVLpcmtlSXCxcITvd4l{KEG|c3H5 MnnSNVAxKM7:TR?= NEfhUWg1QCCq MYDEUXNQ NXTQ[JlKcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> MUmyOFQ5OTV6Nh?=
U251 M2Lqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHaNlQhcA>? NXf0THJbUUN3ME24Ok4zQeLCidMx5qCKOS53ODFOwG0> M3HK[VI1OzJ4OUW0
U251 NGjnUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H5XVQ5KGh? MkW1TWM2OD15NT6zOQKBkcLz4pEJNU4xOiEQvF2= MXWyOFMzPjl3NB?=
U251 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m5blczKGh? NWfYVVNEUUN3ME23Nk41OuLCidMx5qCKOS52NTFOwG0> M2HPblI1OzJ4OUW0
U251 M1;EcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq5OkBp MofQTWM2OD14OT64NwKBkcLz4pEJN{4xPCEQvF2= MUWyOFMzPjl3NB?=
T98G MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fyRVAuPzVyIN88US=> MWG3Nk86PiCq NWnUNJpRcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M4jwe|I1OzJ2MEiw
U251-MG NW\IW4gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKwMVgxOCEQvF2= NGfmeJg4OiCq MoXpbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1TOfVI1ODl|NkOw
D54-MG M{DzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nqPVAuQDByIN88US=> M3joRVczKGh? MVPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MV2yOFA6OzZ|MB?=
SHG-44 NHW2TFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK2NVAuOjByIN88US=> NFPCXnI6PiCq NX\j[4pKUUN3ME25Mlc{KMLzIEKuNVIh|ryP NH3oR|IzPDB4NUW2PS=>
U373  NH7pU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\vb|ExNTJyMDFOwG0> M4niR|k3KGh? NYD3[XRxUUN3ME2xNE4yOyEEsTCxMlAzKM7:TR?= MVmyOFA3PTV4OR?=
HT-29  NXzHPGhlTnWwY4Tpc44hSXO|YYm= MVe1NFAh|ryP MUSyOE81QCCq MWnlcohidmOnczD0bIUhdGW4ZXzzJI9nKM7|LViyRXjDqA>? NF;C[ZUzPDB|OEC2PC=>
PC-3  NYjBbnB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSwMVI2KM7:TR?= NGfTNFc1QCCq M{DDRYlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDwc5RmdnSrYYTl[EBjgSCueXPvdIVv\Q>? NIrGNnUzOzd2NkmzOC=>
PC-3  MmTTRZBweHSxc3nzJGF{e2G7 M4f2XlI2KM7:TR?= NWXUbHFtPDhiaB?= MYjpcoR2[2W|IHHwc5B1d3OrczD3bIlkcCClYX6gZoUheG:2ZX70bYF1\WRiYomgcJlkd3CnbnW= MmPTNlM4PDZ7M{S=
T98G Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTVOVAuPDByIN88US=> NHPqXowyPDRiaB?= M4D2[YlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NVrzN|hTOjN5MUW0PVk>
U87-MG NFmxbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmxNFAhyrWP NGjZcmw4OiCq NXvicI5icW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= MWqyN|Y6Pjd6OB?=
U251-MG NVjSemNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fDSFExOCEEtV2= NXHDbot[PzJiaB?= M3;Ue4lvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ? NVjD[ZB3OjN4OU[3PFg>
LNT-229 NXXCO|JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i3O|MuOTByIN88US=> Mn3qNlQhcA>? MlXobY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NG\wZm0zOzZ4N{[zNi=>
T98G NYHwemlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCxNE04ODBizszN MVyyOEBp NGXOdoxqdmirYnn0d{BkdG:wb3flcolkKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NUnHTVZKOjN4Nke2N|I>
U87  NVO1VYxUTnWwY4Tpc44hSXO|YYm= MVWxNFAhyrWP M2rRU|MhcA>? MkTZ[YxmfmG2ZYOgeIhmKGyndnXsd{Bw\iCyQ3jrNUBidmRicFPob|I> MYWyN|Y3PzR4OR?=
HCT116 NVe2b3FJTnWwY4Tpc44hSXO|YYm= Mk\QNVAxKML3TR?= NUXXeIFSOyCq NVzSPY9RcW6mdXPld{B1cGViQ3jrNUBRcG:|cHjvdplt[XSrb36= NU\6UnIyOjN4Nke0Olk>
HCT3-6 M{LWWmZ2dmO2aX;uJGF{e2G7 NUH4d4NwOTByINM1US=> NEfMT3U{KGh? M2q5bYlv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w MnPiNlM3Pjd2Nkm=
U-87  NXfmSI1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmwMVQxKM7:TR?= MU[xNkBl MoXKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFO2VWQzOzZ2NUeyPS=>
U-87  MUXBdI9xfG:|aYOgRZN{[Xl? NHzDfpkxNTRyIN88US=> MoD1N{83KGR? MXnpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NF3Hem8zOzZ2NUeyPS=>
U-87  NWfzUmtnTnWwY4Tpc44hSXO|YYm= MV:wMVQxKM7:TR?= MWCzM|Yh\A>? NGT3ZpFqdmS3Y3XzJIF2fG:yaHHnfUBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NFHKOpUzOzZ2NUeyPS=>
GB-SCC010 NWG3OmFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LCelQh\A>? M3zze2lEPTB;MkK2JO69VQ>? NXq3e|FXOjN4MUK3OVU>
GB-SCC026 Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7CVpB1PCCm MYrJR|UxRTV|LkGg{txO MX:yN|YyOjd3NR?=
GB-SCC028 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\hOEBl NYLnW2xwUUN3ME2xOlch|ryP MoC4NlM3OTJ5NUW=
U87 M4\zcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi3OEBl M{HmSGlEPTB;NEWuNkDPxE1? MW[yN|YyOjd3NR?=
U87 stem cell NX7aR5htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[0JIQ> NEXwO3lKSzVyPU[2Mlch|ryP M4\wWFI{PjF{N{W1

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pERK / ERK / p-p38 / p38; 

PubMed: 24436439     


Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression.

DR5 / c-FLIP / Survivin / XIAP; 

PubMed: 24436439     


Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours. 

24436439
Growth inhibition assay
Cell viability; 

PubMed: 25751281     


Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.

25751281
Immunofluorescence
Phalloidin / Phospho-H2A.X; 

PubMed: 27375225     


Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). 

cleaved caspase-3; 

PubMed: 25663820     


Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).

27375225 25663820
In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856
Smiles CN1N=NC2=C(N=C[N]2C1=O)C(N)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04238819 Not yet recruiting Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide Relapsed Solid Tumor|Refractory Solid Tumor Eli Lilly and Company July 31 2020 Phase 1
NCT04388475 Not yet recruiting Drug: OKN-007|Drug: Temozolomide (TMZ) Recurrent Malignant Glioma|Brain Glioblastoma Oblato Inc. May 25 2020 Phase 2
NCT03796507 Not yet recruiting Drug: Temozolomide Glioma of Brain University of Rochester|National Institutes of Health (NIH) March 1 2020 Early Phase 1
NCT04200066 Not yet recruiting Drug: Temozolomide Tamoxifen Maprotiline Glioblastoma|Brain Tumor University of Rochester February 1 2020 Phase 1
NCT04091503 Not yet recruiting Drug: Intranasal Modified Temozolomide Glioma Malignant|Gliosarcoma|Astrocytoma of Brain Center Trials & Treatment Europe December 10 2019 Phase 1
NCT03932981 Recruiting Drug: Temozolomide Adult Brainstem Glioma Assistance Publique - Hôpitaux de Paris July 26 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Temozolomide|Temozolomide ic50|Temozolomide price|Temozolomide cost|Temozolomide solubility dmso|Temozolomide purchase|Temozolomide manufacturer|Temozolomide research buy|Temozolomide order|Temozolomide mouse|Temozolomide chemical structure|Temozolomide mw|Temozolomide molecular weight|Temozolomide datasheet|Temozolomide supplier|Temozolomide in vitro|Temozolomide cell line|Temozolomide concentration|Temozolomide nmr|Temozolomide in vivo|Temozolomide clinical trial|Temozolomide inhibitor|Temozolomide DNA Damage inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID